A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Autor: Belderbos, Robert A., Baas, Paul, Berardi, Rossana, Cornelissen, Robin, Fennell, Dean A., van Meerbeeck, Jan, Scherpereel, Arnaud, Vroman, Heleen, Aerts, Joachim G. J., V, Bezemer, K., Rafaelian, A., Poncin, M., Goktas, I, Braakman, E., van Hove, L., Klok, J., Geel, A., de Vries, M., Janssens, Annelies, Zhang, Xiang, Raskin, Jo, Kohl, Siska, Hufkens, Annemie, Claes, Rita, Willemin, M. C., Wasielewski, E., Grammont, M., Batista, S., Pinturaud, M., Ballatore, Z., Lucarelli, A., Burattini, M., Tonnini, C., Bianchi, F., Pagliaretta, S., Hudka, M., Lord, K., Darlison, L., Varadhan, B., Hunter, A.

Publikováno v: Translational lung cancer research
Translational Lung Cancer Research, 8(3), 280-285. Society for Translational Medicine (STM)
Translational Lung Cancer Research

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. Adjuvant bevaci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f521f512f42d764c2b193c5aaf43990
https://hdl.handle.net/10067/1613550151162165141

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.